Targeted Brain Derived Neurotropic Factors (BDNF) Delivery across the Blood-Brain Barrier for Neuro-Protection Using Magnetic Nano Carriers: An In-Vitro Study

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Pilakka Kanthikeel, Sudheesh ^a   Atluri, Venkata Subba Rao ^a   Sagar, Vidya ^a   Saxena, Shailendra ^b   Nair, Madhavan ^a  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DRUG CARRIER; MAGNETIC NANOPARTICLE; NANOCARRIER;

APOPTOSIS; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG PENETRATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; NANOPHARMACEUTICS; NEUROPROTECTION; PROTEIN EXPRESSION; PROTEIN TARGETING;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84876961579     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062241     Document Type: Article

References (72)

1. Han B, Gfroerer JC, Colliver JD, Penne MA, (2009) Substance use disorder among older adults in the United States in 2020. Addiction 104: 88-96.
2. Guo CJ, Li Y, Tian S, Wang X, Douglas SD, et al. (2002) Morphine enhances HIV infection of human blood mononuclear phagocytes through modulation of beta-chemokines and CCR5 receptor. J Investig Med 50: 435-442.
3. Purohit V, Rapaka R, Shurtleff D, (2011) Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia. Mol Neurobiol 44: 102-110.
4. Mansour A, Fox CA, Akil H, Watson SJ, (1995) Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 18: 22-29.
5. Wallace DR, (2006) HIV neurotoxicity: potential therapeutic interventions. J Biomed Biotechnol 2006: 65741.
6. Nair MP, Schwartz SA, Polasani R, Hou J, Sweet A, et al. (1997) Immunoregulatory effects of morphine on human lymphocytes. Clin Diagn Lab Immunol 4: 127-132.
7. Yin D, Mufson RA, Wang R, Shi Y, (1999) Fas-mediated cell death promoted by opioids. Nature 397: 218.
8. Singhal PC, Sharma P, Kapasi AA, Reddy K, Franki N, et al. (1998) Morphine enhances macrophage apoptosis. J Immunol 160: 1886-1893.
9. Ayre SG, (1989) New approaches to the delivery of drugs to the brain. Med Hypotheses 29: 283-291.
10. Hurwitz AA, Berman JW, Lyman WD, (1994) The role of the blood-brain barrier in HIV infection of the central nervous system. Adv Neuroimmunol 4: 249-256.
11. Betz AL, Goldstein GW, (1986) Specialized properties and solute transport in brain capillaries. Annu Rev Physiol 48: 241-250.
12. Itoh K, Mehraein P, Weis S, (2000) Neuronal damage of the substantia nigra in HIV-1 infected brains. Acta Neuropathol 99: 376-384.
13. Wang GJ, Chang L, Volkow ND, Telang F, Logan J, et al. (2004) Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 127: 2452-2458.
14. Nosheny RL, Ahmed F, Yakovlev A, Meyer EM, Ren K, et al. (2007) Brain-derived neurotrophic factor prevents the nigrostriatal degeneration induced by human immunodeficiency virus-1 glycoprotein 120 in vivo. Eur J Neurosci 25: 2275-2284.
15. Bachis A, Major EO, Mocchetti I, (2003) Brain-derived neurotrophic factor inhibits human immunodeficiency virus-1/gp120-mediated cerebellar granule cell death by preventing gp120 internalization. J Neurosci 23: 5715-5722.
16. Mocchetti I, Nosheny RL, Tanda G, Ren K, Meyer EM, (2007) Brain-derived neurotrophic factor prevents human immunodeficiency virus type 1 protein gp120 neurotoxicity in the rat nigrostriatal system. Ann N Y Acad Sci 1122: 144-154.
17. Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, et al. (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350: 230-232.
18. Altar CA, Boylan CB, Jackson C, Hershenson S, Miller J, et al. (1992) Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc Natl Acad Sci U S A 89: 11347-11351.
19. Mamounas LA, Blue ME, Siuciak JA, Altar CA, (1995) Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. J Neurosci 15: 7929-7939.
20. Han BH, D'Costa A, Back SA, Parsadanian M, Patel S, et al. (2000) BDNF blocks caspase-3 activation in neonatal hypoxia-ischemia. Neurobiol Dis 7: 38-53.
21. Pardridge WM, (2007) Blood-brain barrier delivery. Drug Discov Today 12: 54-61.
22. Pardridge WM, Wu D, Sakane T, (1998) Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration. Pharm Res 15: 576-582.
23. Suri SS, Fenniri H, Singh B, (2007) Nanotechnology-based drug delivery systems. J Occup Med Toxicol 2: 16.
24. Saiyed ZM, Sharma S, Godawat R, Telang SD, Ramchand CN, (2007) Activity and stability of alkaline phosphatase (ALP) immobilized onto magnetic nanoparticles (Fe3O4). J Biotechnol 131: 240-244.
25. Saiyed ZM, Parasramka M, Telang SD, Ramchand CN, (2007) Extraction of DNA from agarose gel using magnetic nanoparticles (magnetite or Fe3O4). Anal Biochem 363: 288-290.
26. Boyum A, (1968) Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 97: 77-89.
27. Gandhi N, Saiyed ZM, Napuri J, Samikkannu T, Reddy PV, et al. (2010) Interactive role of human immunodeficiency virus type 1 (HIV-1) clade-specific Tat protein and cocaine in blood-brain barrier dysfunction: implications for HIV-1-associated neurocognitive disorder. J Neurovirol 16: 294-305.
28. Persidsky Y, Stins M, Way D, Witte MH, Weinand M, et al. (1997) A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. J Immunol 158: 3499-3510.
29. Mahajan SD, Schwartz SA, Aalinkeel R, Chawda RP, Sykes DE, et al. (2005) Morphine modulates chemokine gene regulation in normal human astrocytes. Clin Immunol 115: 323-332.
30. Smith DL, Pozueta J, Gong B, Arancio O, Shelanski M, (2009) Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc Natl Acad Sci U S A 106: 16877-16882.
31. Xia Y, Wang CZ, Liu J, Anastasio NC, Johnson KM, (2010) Brain-derived neurotrophic factor prevents phencyclidine-induced apoptosis in developing brain by parallel activation of both the ERK and PI-3K/Akt pathways. Neuropharmacology 58: 330-336.
32. Kwon M, Fernandez JR, Zegarek GF, Lo SB, Firestein BL, (2011) BDNF-promoted increases in proximal dendrites occur via CREB-dependent transcriptional regulation of cypin. J Neurosci 31: 9735-9745.
33. Li Y, Wang H, Niu L, Zhou Y, (2007) Chronic morphine exposure alters the dendritic morphology of pyramidal neurons in visual cortex of rats. Neurosci Lett 418: 227-231.
34. Bramham CR, Messaoudi E, (2005) BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog Neurobiol 76: 99-125.
35. Chapleau CA, Carlo ME, Larimore JL, Pozzo-Miller L, (2008) The actions of BDNF on dendritic spine density and morphology in organotypic slice cultures depend on the presence of serum in culture media. J Neurosci Methods 169: 182-190.
36. Roy S, Loh HH, (1996) Effects of opioids on the immune system. Neurochem Res 21: 1375-1386.
37. Stefano GB, Scharrer B, Smith EM, Hughes TK Jr, Magazine HI, et al. (1996) Opioid and opiate immunoregulatory processes. Crit Rev Immunol 16: 109-144.
38. Strathdee SA, Stockman JK, (2010) Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions. Curr HIV/AIDS Rep 7: 99-106.
39. Alcala-Barraza SR, Lee MS, Hanson LR, McDonald AA, Frey WH, et al. (2010) Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J Drug Target 18: 179-190.
40. James HJ, Sharer LR, Zhang Q, Wang HG, Epstein LG, et al. (1999) Expression of caspase-3 in brains from paediatric patients with HIV-1 encephalitis. Neuropathol Appl Neurobiol 25: 380-386.
41. Garden GA, Budd SL, Tsai E, Hanson L, Kaul M, et al. (2002) Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci 22: 4015-4024.
42. Poduslo JF, Curran GL, (1996) Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res 36: 280-286.
43. Thorne RG, Frey WH, 2nd (2001) Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 40: 907-946.
44. Betz AL, Goldstein GW, (1978) Polarity of the blood-brain barrier: neutral amino acid transport into isolated brain capillaries. Science 202: 225-227.
45. Betz AL, Firth JA, Goldstein GW, (1980) Polarity of the blood-brain barrier: distribution of enzymes between the luminal and antiluminal membranes of brain capillary endothelial cells. Brain Res 192: 17-28.
46. Mandel RJ, Gage FH, Clevenger DG, Spratt SK, Snyder RO, et al. (1999) Nerve growth factor expressed in the medial septum following in vivo gene delivery using a recombinant adeno-associated viral vector protects cholinergic neurons from fimbria-fornix lesion-induced degeneration. Exp Neurol 155: 59-64.
47. Blits B, Oudega M, Boer GJ, Bartlett Bunge M, Verhaagen J, (2003) Adeno-associated viral vector-mediated neurotrophin gene transfer in the injured adult rat spinal cord improves hind-limb function. Neuroscience 118: 271-281.
48. Williams LR, Varon S, Peterson GM, Wictorin K, Fischer W, et al. (1986) Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci U S A 83: 9231-9235.
49. Thoenen H, Sendtner M, (2002) Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat Neurosci 5Suppl: 1046-1050.
50. Silva GA, (2007) Nanotechnology approaches for drug and small molecule delivery across the blood brain barrier. Surg Neurol 67: 113-116.
51. Saiyed ZM, Gandhi NH, Nair MP, (2010) Magnetic nanoformulation of azidothymidine 5′-triphosphate for targeted delivery across the blood-brain barrier. Int J Nanomedicine 5: 157-166.
52. Chertok B, Moffat BA, David AE, Yu F, Bergemann C, et al. (2008) Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 29: 487-496.
53. Ito A, Shinkai M, Honda H, Kobayashi T, (2005) Medical application of functionalized magnetic nanoparticles. J Biosci Bioeng 100: 1-11.
54. Alexiou C, Schmid RJ, Jurgons R, Kremer M, Wanner G, et al. (2006) Targeting cancer cells: magnetic nanoparticles as drug carriers. Eur Biophys J 35: 446-450.
55. Lubbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, et al. (1996) Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res 56: 4694-4701.
56. Kwon SG, Piao Y, Park J, Angappane S, Jo Y, et al. (2007) Kinetics of monodisperse iron oxide nanocrystal formation by "heating-up" process. J Am Chem Soc 129: 12571-12584.
57. Saiyed ZM, Gandhi NH, Nair MP, (2009) AZT 5′-triphosphate nanoformulation suppresses human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells. J Neurovirol 15: 343-347.
58. Kaul M, Garden GA, Lipton SA, (2001) Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410: 988-994.
59. Goswami R, Dawson SA, Dawson G, (1998) Cyclic AMP protects against staurosporine and wortmannin-induced apoptosis and opioid-enhanced apoptosis in both embryonic and immortalized (F-11kappa7) neurons. J Neurochem 70: 1376-1382.
60. Singhal PC, Kapasi AA, Reddy K, Franki N, Gibbons N, et al. (1999) Morphine promotes apoptosis in Jurkat cells. J Leukoc Biol 66: 650-658.
61. Freier DO, Fuchs BA, (1993) Morphine-induced alterations in thymocyte subpopulations of B6C3F1 mice. J Pharmacol Exp Ther 265: 81-88.
62. Fuchs BA, Pruett SB, (1993) Morphine induces apoptosis in murine thymocytes in vivo but not in vitro: involvement of both opiate and glucocorticoid receptors. J Pharmacol Exp Ther 266: 417-423.
63. Bourtchuladze R, Frenguelli B, Blendy J, Cioffi D, Schutz G, et al. (1994) Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein. Cell 79: 59-68.
64. Bernabeu R, Bevilaqua L, Ardenghi P, Bromberg E, Schmitz P, et al. (1997) Involvement of hippocampal cAMP/cAMP-dependent protein kinase signaling pathways in a late memory consolidation phase of aversively motivated learning in rats. Proc Natl Acad Sci U S A 94: 7041-7046.
65. Taubenfeld SM, Wiig KA, Bear MF, Alberini CM, (1999) A molecular correlate of memory and amnesia in the hippocampus. Nat Neurosci 2: 309-310.
66. Cammarota M, Bevilaqua LR, Ardenghi P, Paratcha G, Levi de Stein M, et al. (2000) Learning-associated activation of nuclear MAPK, CREB and Elk-1, along with Fos production, in the rat hippocampus after a one-trial avoidance learning: abolition by NMDA receptor blockade. Brain Res Mol Brain Res 76: 36-46.
67. Viola H, Furman M, Izquierdo LA, Alonso M, Barros DM, et al. (2000) Phosphorylated cAMP response element-binding protein as a molecular marker of memory processing in rat hippocampus: effect of novelty. J Neurosci 20: RC112.
68. Alonso M, Bekinschtein P, Cammarota M, Vianna MR, Izquierdo I, et al. (2005) Endogenous BDNF is required for long-term memory formation in the rat parietal cortex. Learn Mem 12: 504-510.
69. Sarti F, Borgland SL, Kharazia VN, Bonci A, (2007) Acute cocaine exposure alters spine density and long-term potentiation in the ventral tegmental area. Eur J Neurosci 26: 749-756.
70. Frankfurt M, Salas-Ramirez K, Friedman E, Luine V, (2011) Cocaine alters dendritic spine density in cortical and subcortical brain regions of the postpartum and virgin female rat. Synapse 65: 955-961.
71. Nestler EJ, (2001) Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2: 119-128.
72. Robinson TE, Kolb B, (1999) Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine. Eur J Neurosci 11: 1598-1604.